GSK has adopted a strategy that aims to balance its operations between Western and Eastern markets, according to a company executive. The approach emerged after a licensing deal with Hansoh, a Chinese biopharma, proved successful and highlighted the potential of sourcing drugs from China.
The executive said the Hansoh deal, which took place two years ago, opened GSK's eyes to the possibilities of licensing from China. Since then, the company has been working to integrate Eastern opportunities into its broader portfolio.
This report is based on a single article from Fierce Biotech, so there is no independent corroboration. However, the executive's comments suggest that GSK views China as a key part of its future drug development and licensing strategy.